New clinical data analysis confirms that the first-in-class direct renin inhibitor Rasilez® (aliskiren), known as Tekturna® in the US, provides significantly greater blood pressure reductions in obese patients with high blood pressure compared to the diuretic hydrochlorothiazide (HCT) alone1.
More...